Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Multiple Myeloma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Large B-Cell, Diffuse 2Fallopian Tube Neoplasms 2Uveal Melanoma 1Thymoma 1Solitary Fibrous Tumor, Pleural 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasms, Unknown Primary 1Neoplasms, Plasma Cell 1Neoplasms 1Mesothelioma, Malignant 1Mediastinal Neoplasms 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Myeloid, Acute 1Glioblastoma 1Eye Neoplasms 1Congenital Abnormalities 1Carcinoma, Ovarian Epithelial 1Carcinoma, Neuroendocrine 1Burkitt Lymphoma 1Brenner Tumor 1Bone Marrow Neoplasms 1

Interventions

montanide ISA 51 1binimetinib 1belinostat 1Proton Therapy 1Peptides 1Melphalan 1MART-1 Antigen 1MAGEA3 protein, human 1Leuprolide 1Lasers 1Laparotomy 1Interleukin-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Eye Neoplasms × belinostat × Clear all
NCT05170334 2026-04-06

Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
7 enrolled
Dermatologic

Uveal Melanoma, Eye Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡